vimarsana.com
Home
Live Updates
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting : vimarsana.com
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting
-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached...
Related Keywords
United States ,
Mccormick Place ,
Illinois ,
Chicago ,
American ,
Laura Morgan ,
Myesha Lacy ,
Matthewj Frigault ,
Cellular Therapy Service At Mass ,
International Myeloma Working Group ,
American Society Of Clinical Oncology ,
Mccormick Place Convention Center ,
Drug Administration ,
Cancer Center ,
Instructor At Harvard Medical School ,
Prnewswire Arcellx Inc ,
Nasdaq ,
Sam Brown Inc ,
Exchange Commission ,
Arcellx Inc ,
Securities Exchange ,
Clinical Oncology ,
Assistant Director ,
Cellular Therapy Service ,
Mass General Cancer Center ,
Harvard Medical School ,
Rami Elghandour ,
Chief Executive ,
Presentation Details ,
Refractory Multiple ,
Harvard Medical ,
Oral Abstract ,
Hematologic Malignancies ,
Plasma Cell ,
Fast Track ,
Orphan Drug ,
Regenerative Medicine Advanced Therapy ,
Securities Act ,
Securities Exchange Act ,
Risk Factors ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Arcellx ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.